
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam Inc. is positioned for significant growth in the medical technology sector, driven by its innovative Vector Electrocardiography (VECG) platform, which has shown strong equivalence to existing 12-lead systems, enhancing approval prospects and market adoption as it seeks FDA clearance for its telehealth products. The potential expansion into a $1.3 to $2.6 billion annual revenue stream targeting elevated-risk patients underscores the company's promising financial outlook, especially in light of the rapidly growing global mobile ECG devices market, projected to rise from $4.1 billion in 2024 to $8.9 billion by 2032. Additionally, the mobile healthcare devices market's anticipated growth from $155 billion in 2025 to $745.7 billion by 2035 at a 17% CAGR further demonstrates the substantial market demand for HeartBeam's solutions, positioning the company favorably within the healthcare landscape.
Bears say
HeartBeam Inc faces significant financial challenges that contribute to a negative outlook for its stock. The company may struggle with demand for its products due to potential issues surrounding reimbursement, which, coupled with a weak performance in its ECG systems, could hinder revenue generation and operational results. Furthermore, the auditors’ going-concern opinion highlights serious doubts about the company’s sustainability without new funding, indicating that prolonged negative cash flows could lead to adverse operational decisions, further pressuring the stock.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares